January 20, 2026

Evotec SE (EVO): Analyst Consensus Foresees 54% Upside Potential Amidst Strategic Partnerships

Evotec SE (EVO), a prominent player in the healthcare sector under the umbrella of drug manufacturers specializing in both specialty and generic medications, continues to attract attention from investors with..

PROCEPT BioRobotics (PRCT) Stock Analysis: Navigating a 66.98% Potential Upside in the Medical Device Sector

PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a pioneer in the healthcare sector, is making waves in the medical device industry with its innovative surgical robotics solutions. Headquartered in San Jose, California,..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Biotech Innovator Poised for 14% Upside Potential

PTC Therapeutics, Inc. (NASDAQ: PTCT), a prominent player in the biotechnology sector, is gaining attention from investors due to its promising growth prospects and strategic position in the healthcare market...

GRAIL, Inc. (GRAL) Investor Outlook: Assessing the 8.58% Potential Upside in Healthcare Diagnostics

GRAIL, Inc. (GRAL), a standout player in the healthcare diagnostics and research sector, is capturing investor attention with a promising 8.58% potential upside. As a commercial-stage company focused on multi-cancer..

Liquidia Corporation (LQDA) Stock Analysis: Exploring the 20% Upside Potential Amidst Groundbreaking Revenue Growth

Liquidia Corporation (NASDAQ: LQDA), a promising player in the biotechnology sector, has captured the attention of investors with its impressive revenue growth and potential upside. Based in Morrisville, North Carolina,..

National HealthCare Corporation (NHC) Stock Analysis: Steady Revenue Growth Amidst Unrated Territory

National HealthCare Corporation (NYSE: NHC) operates within the healthcare sector, specializing in medical care facilities. With a market capitalization of $2.13 billion, the company is a significant player in the..

Neogen Corporation (NEOG) Stock Analysis: Exploring a 26.13% Potential Upside Amidst Challenging Metrics

Investors are taking a keen look at Neogen Corporation (NYSE: NEOG), a prominent player in the diagnostics and research industry with a focus on food and animal safety. With a..

Centessa Pharmaceuticals (CNTA) Stock Analysis: Exploring a 76.77% Potential Upside in the Biotech Sector

Investors with an eye on the healthcare sector may find Centessa Pharmaceuticals plc (NASDAQ: CNTA) an intriguing opportunity. This UK-based biotechnology company, with a market capitalization of $3.28 billion, has..

Immunocore Holdings plc (IMCR)

⚠️ No article content returned.

..

Enovis Corporation (ENOV) Stock Analysis: Exploring the Healthcare Innovator’s 89.63% Potential Upside

Enovis Corporation (NYSE: ENOV), a key player in the medical devices industry, has been catching the eyes of investors with its impressive potential upside of 89.63%. As a healthcare company..

Warby Parker Inc. (WRBY) Stock Analysis: Can This Eyewear Innovator Maintain Its 15.2% Revenue Growth?

Warby Parker Inc. (NYSE: WRBY) has emerged as a significant player in the healthcare sector, specifically within the medical instruments and supplies industry. Best known for revolutionizing the eyewear market..

Tarsus Pharmaceuticals (TARS) Stock Analysis: A Promising Biotech Player with a 23% Upside Potential

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company dedicated to eye care innovation, is garnering significant attention from investors. With a market capitalization of $3.02 billion, Tarsus operates within the..

Structure Therapeutics Inc. (GPCR) Stock Analysis: A Biotech Star with 14.83% Potential Upside

Structure Therapeutics Inc. (NASDAQ: GPCR) is drawing significant attention in the biotechnology sector, promising innovative treatments for chronic diseases while showcasing an impressive market trajectory. With a market capitalization of..

Beam Therapeutics Inc. (BEAM): Investor Outlook with a 44.78% Potential Upside

Beam Therapeutics Inc. (NASDAQ: BEAM), a Cambridge, Massachusetts-based biotechnology company, is capturing investor attention with its innovative approach to precision genetic medicines. Despite the challenges inherent in the biotech sector,..

Tandem Diabetes Care, Inc. (TNDM) Investor Outlook: Navigating Potential Upside in the Medical Devices Market

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) stands as a noteworthy player in the healthcare sector, specifically within the medical devices industry. With its headquarters in San Diego, California, Tandem focuses..

IDEAYA Biosciences (IDYA) Stock Analysis: A Promising Upside of 38.69% in Precision Medicine

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a prominent player in the biotechnology sector, is making waves with its innovative approach to precision medicine oncology. With a market capitalization of $3.14 billion,..

Mesoblast Limited (MESO) Stock Analysis: 100% Upside Potential in Biotech Breakthrough

Mesoblast Limited (MESO), an Australian biotechnology company, is capturing the attention of investors with a staggering potential upside of 100.57%. Specializing in regenerative medicine, Mesoblast is leveraging its proprietary technology..

Indivior PLC (INDV) Investor Outlook: A 35.66% Potential Upside with Strong Buy Ratings

Indivior PLC (INDV), a prominent player in the healthcare sector, is capturing significant investor attention with its robust position in the drug manufacturing industry, particularly in specialty and generic pharmaceuticals...

Clover Health Investments, Corp (CLOV) Stock Analysis: Unpacking a 27.3% Potential Upside

For investors eyeing the healthcare sector, Clover Health Investments, Corp (NASDAQ: CLOV) presents a mix of challenges and opportunities. With a market capitalization of $1.31 billion, Clover Health stands as..

AtriCure, Inc. (ATRC) Stock Analysis: A Promising 35% Upside Potential Amid Strong Buy Ratings

AtriCure, Inc. (NASDAQ: ATRC), a key player in the healthcare sector specializing in medical instruments and supplies, presents an intriguing investment opportunity for those seeking exposure to the rapidly advancing..

Search

Funds

January 20, 2026

Search

Funds

January 20, 2026

FTSE 100

Funds